Tài liệu Báo cáo khoa học: TEC family kinases in health and disease – loss-of-function of BTK and ITK and the gain-of-function fusions ITK–SYK and BTK–SYK pptx

MINIREVIEW TEC family kinases in health and disease – loss-of-function of BTK and ITK and the gain-of-function fusions ITK–SYK and BTK–SYK Alamdar Hussain 1,2, *, Liang Yu 1,3, *, Rani Faryal 1,2 , Dara K. Mohammad 1 , Abdalla J. Mohamed 1,4 and C. I. Edvard Smith 1 1 Clinical Research Center, Department of Laboratory Medicine, Karolinska Institutet, Huddinge University Hospital, Sweden 2 Department of Biosciences, COMSATS Institute of Information Technology, Islamabad, Pakistan 3 Department of Hematology, Huaian No. 1 Hospital, Nanjing Medical University, Huaian, Jiangsu, China 4 Faculty of Science (Biology), Universiti Brunei Darussalam, Gadong, Brunei Darussalam Introduction TEC family kinases (TFKs) evolved 600 million years ago prior to the existence of metazoans [1] and com- prise five members in mammals: Bruton’s tyrosine kinase (BTK), inducible T-cell kinase (ITK), TEC, BMX [also known as epithelial and endothelial tyro- sine kinase (ETK)] and TXK [also known as resting lymphocyte kinase (RLK)]. The phenotypes of loss-of- function mutations in mammals mainly affect the hematopoietic system, whereas, in fruit fly oogenesis, male genital development and life span are compro- mised, a phenotype partially reversed by the expression of human BTK [2]. Many reviews, mainly concentrat- ing on intracellular signaling, have been written on TFKs [3–7]. In this minireview, we focus on human Keywords AKT; BMX; BTK; ITK; lymphocyte; PH domain; RLK; TEC; TXK; X-linked agammaglobulinemia Correspondence L. Yu, Department of Hematology, Huaian No. 1 Hospital, Nanjing Medical University, Huaian 223300, Jiangsu, China Fax: +86 517 84907078 Tel: +86 517 84952303 E-mail: liang.yu@ki.se *These authors contributed equally to this work (Received 31 August 2010, revised 21 March 2011, accepted 20 April 2011) doi:10.1111/j.1742-4658.2011.08134.x The TEC family is ancient and constitutes the second largest family of cyto- plasmic tyrosine kinases. In 1993, loss-of-function mutations in the BTK gene were reported as the cause of X-linked agammaglobulinemia. Of all the existing 90 tyrosine kinases in humans, Bruton’s tyrosine kinase (BTK) is the kinase for which most mutations have been identified. These experi- ments of nature collectively provide a form of mutation scanning with direct implications for the several hundred endogenous signaling proteins carrying domains also found in BTK. In 2009, an inactivating mutation in the ITK gene was shown to cause susceptibility to lethal Epstein–Barr virus infec- tion. Both kinases represent interesting targets for inhibition: in the case of BTK, as an immunosuppressant, whereas there is evidence that the inhibi- tion of inducible T-cell kinase (ITK) could influence the infectivity of HIV and also have anti-inflammatory activity. Since 2006, several patients carry- ing a fusion protein, originating from a translocation joining genes encoding the kinases ITK and spleen tyrosine kinase (SYK), have been shown to develop T-cell lymphoma. We review these disease processes and also describe the role of the N-terminal pleckstrin homology–Tec homology (PH–TH) domain doublet of BTK and ITK in the downstream intracellular signaling of such fusion proteins. Abbreviations AKT, v-akt murine thymoma viral oncogene; BTK, Bruton’s tyrosine kinase; EBV, Epstein–Barr virus; ITK, inducible T-cell kinase; NKT cell, natural killer T cell; PH, pleckstrin homology; PKB, protein kinase B; R28C, arginine 28 mutated to cysteine; SH2, Src homology 2; SH3, Src homology 3; SYK, spleen tyrosine kinase; TFK, TEC family kinase; TH, Tec homology; XLA, X-linked agammaglobulinemia. FEBS Journal 278 (2011) 2001–2010 ª 2011 The Authors Journal compilation ª 2011 FEBS 2001 disease, in which TFKs are showing increasing impor- tance, both as an underlying cause, but recently also as potential targets for new drugs. The main emphasis is on BTK and ITK deficiency, as well as the translo- cation between ITK and spleen tyrosine kinase (SYK). Very recently, the TXK ⁄ TEC loci have also been asso- ciated with disease, namely the development of rheu- matoid arthritis, in a genome-wide screen [8]. Mutations affecting BTK cause X-linked agammaglobulinemia (XLA) and provide insight into basic signaling mechanisms In 1992, two TFKs were already known, namely TEC and ITK (reviewed in Ref. [1]). Even though informa- tion was available regarding their potential function, it was the identification of BTK, as the kinase affected in XLA [9,10], which immediately made TFKs known to the wider scientific community. In the same year, the xid (X-linked immunodeficiency) mouse was recog- nized as a spontaneously occurring animal disease model for inactivating mutations affecting this kinase [11,12]. However, the phenotype in the xid mouse is mild, whereas the identical mutation, causing the sub- stitution of arginine 28 for cysteine (R28C), in humans [13] results in classical XLA, clearly demonstrating that there are species’ differences. Ellmeier et al. [14] reported that the combined inactivation of BTK and TEC in mice causes a phenotype resembling XLA, thus delineating species-specific redundancy. The R28C mutation, which abolishes binding to activation- induced phosphatidylinositol-3,4,5-trisphosphate in the cell membrane [15], was soon engineered and grafted onto other signaling molecules, such as v-akt murine thymoma viral oncogene (AKT) [also known as pro- tein kinase B (PKB)]. In AKT, a cysteine substitution of the corresponding R25 in the pleckstrin homology (PH) domain also results in loss of function [16,17], thereby demonstrating related functions among selected PH domains. Thus, from the beginning, muta- tions in the BTK gene have contributed to our under- standing of signaling mechanisms in general. Mutation spectrum in XLA and genotype–phenotype correlations Figure 1 depicts the linear organization of the domains in BTK and Fig. 2 shows missense mutations (amino acid substitutions) in a three-dimensional context in the various domains of BTK. Mutations affecting the R28 residue (marked in dark blue in Fig. 1) will result in the redistribution of electrostatic charges that are Fig. 1. Structure of PH, SH2 and kinase domains of BTK with color- ing of residues affected by missense mutations. Top left: locations of the missense mutation in the BTK PH domain; arginine 28 is in dark blue, encircled in red. Bottom left: SH2 domain. Right: kinase domain. The mutated residues are indicated in yellow, a-helices are in cyan, b-sheets are in magenta and loops are in blue. Modified from Valiaho et al. [19]. Fig. 2. (A) Schematic representation of BTK, ITK, SYK and the cor- responding fusion proteins. PH, pleckstrin homology domain; TH, Tec homology domain; SH3, Src homology 3 domain; SH2, Src homology 2 domain; Y, linker region tyrosine (Y352); YY, activation loop tyrosines (Y525 ⁄ Y526). (B) Graphic representation showing that the PH–TH domain differences between BTK–SYK and ITK– SYK fusion proteins lead to differential phosphorylation levels of the fusion proteins themselves, as well as the downstream adapter proteins SLP76 and BLNK, in 293T and COS7 cells. Size of red encircled ‘P’ approximately represents the phosphorylation levels. TEC kinases and disease A. Hussain et al. 2002 FEBS Journal 278 (2011) 2001–2010 ª 2011 The Authors Journal compilation ª 2011 FEBS indispensible for ligand binding. Many of the muta- tions locate to highly structurally conserved regions, such as a-helices or b-sheets, whereas some are posi- tioned in the connecting loops. Approximately one- third of all mutations in the BTK gene are missense and some of these reduce the stability of the protein. This is exemplified by mutations in the BTK motif of the Tec homology (TH) domain [18]. This region is known to bind a Zn 2+ ion, rendering stability to the adjacent PH domain. The substitution of conserved Zn 2+ -interacting amino acids results in the formation of a highly unstable protein, which is essentially unde- tectable in cell lysates. A more detailed description of missense mutations in the PH, TH, Src homology 2 (SH2) and kinase domains is given in Ref. [19]. Many other BTK missense mutant proteins are expressed at normal, or close to normal, levels and are instead functionally disabled. We will not survey the different BTK mutations, but instead refer to reports addressing this topic [19–22]. However, just to mention a few specifics, the online database for mutations in the BTK gene, designated BTKbase, http://bio- inf.uta.fi/BTKbase/, contains more than 1100 entries [19–21]. This represents in excess of 970 unrelated fam- ilies showing more than 600 unique molecular events. These numbers clearly demonstrate that, currently, most mutations are unique, i.e. only reported from a single family. This is especially true for frameshift mutations, even though recurrent mutations eventually will prevail here also as the overall number of muta- tions increases. Of the residues affected by missense mutations, proline residues are over-represented, pre- sumably secondary to the strong influence of prolines on peptide folding [21]. Thus, proline is a rigid amino acid creating a fixed kink in a protein chain. Similar to the situation in many other genes, CpG dinucleotides in the BTK gene are more susceptible to mutation, approximately by an order of magnitude [21]. Owing to the high frequency of CpG dinucleo- tides in arginine codons, the mutation spectrum pro- vides a few highly significant genotype–phenotype correlations. Thus, certain codons, such as those encoding R13 and R288 in the PH and SH2 domains of BTK, respectively, are permissive for missense, but not for nonsense, changes, as there are no reported XLA patients with an R13 or R288 substitution, but plenty with stop codons [21]. Conversely, for other arginine codons, corresponding to, for example, R520 and R525, located in the kinase domain, both non- sense and missense mutations cause XLA (P < 0.001). This provides immediate insight into potential con- formational restrictions, as ‘tolerated’ BTK substitu- tions, exchanging R13 or R288 for other amino acids, presumably exist in the general population as rare, normal variants with maintained signaling function. To date, such rare variants have not been described, but, owing to their expected extremely low frequency, this outcome is anticipated. Recently, a rare variant, a nonpathogenic mutation predicted to affect the BTK SH3 domain by generating an A230V amino acid sub- stitution, was reported [23]. Structural analysis shows that this residue is located in the RT loop of the SH3 domain, which is involved in the recognition of inter- acting partners [24]. Although the genotype–phenotype correlation for highly selected residues is extremely strong, the overall correlation based on reported patients is weak, with only a modest over-representation of substitutions rela- tive to frameshifts among patients with mild disease [20,21,25]. This is most probably a result of the fact that more subtle phenotypic changes only rarely lead to genetic analysis, and these mutations are therefore absent from the statistics. To this end, it seems likely that future genome sequencing efforts, where large populations are analyzed, will also identify individuals with mild disease, thereby providing the missing data. The phenotype of XLA and the potential of BTK and ITK inhibitors The outcome of defective BTK signaling in humans has been described previously in detail [26,27], and therefore we will only review this topic very briefly. Patients with XLA have a differentiation block result- ing in an almost complete absence of B lymphocytes and plasma cells and very low levels of immunoglobu- lins of all classes. Humoral immune responses are essentially nonexistent. T cells are not affected, but myeloid cells show demonstrable abnormalities (see minireview by Ellmeier et al. [28]). Patients with XLA are very susceptible to pyogenic bacterial infections but, as these normally can be successfully treated with antibiotics, enteroviruses constitute a greater threat, owing to the fact that these infections are very difficult to treat [29]. Prophylaxis in the form of c-globulin replacement is standard for all patients [30,31]. Over the last few years, several companies have devel- oped small-molecule inhibitors for BTK [32] and ITK [33,34]. ITK inhibitors may potentially be used for the treatment of inflammatory diseases [34] and, as discussed below, may also become part of the anti-HIV therapeu- tic arsenal. By blocking B-lymphocyte development, BTK inhibitors could potentially replace treatment with monoclonal antibodies directed against B-lymphocyte surface antigens, currently a multibillion dollar market. To this end, even after withdrawal, such monoclonals A. Hussain et al. TEC kinases and disease FEBS Journal 278 (2011) 2001–2010 ª 2011 The Authors Journal compilation ª 2011 FEBS 2003 continue to suppress B-lymphocyte levels for long time periods, and it would be of great interest if the effect of BTK inhibitors could be more quickly reversed. A mutation affecting ITK causes susceptibility to Epstein–Barr virus (EBV) infection Although a multitude of disease-causing mutations in the BTK gene have been identified, it was only in 2009 that a spontaneous alteration in another human TFK gene was reported, namely in the ITK gene [35]. ITK was discovered using a degenerate PCR screen for novel T-cell-expressed kinases [36,37]. This enzyme serves as an important player in inflammatory disor- ders, such as allergic asthma and atopic dermatitis [38,39]. In this minireview series, two articles describe the current understanding of ITK’s role in signaling and development [40,41]. Thus, in 2009, Huck et al. [35] identified two sisters from a consanguineous Turkish family who both died after developing severe immune dysregulation follow- ing infection with EBV. Detailed analysis revealed that they were homozygous for a missense mutation in the ITK gene, located on chromosome 5q31-5q32. This resulted in an amino acid substitution (R335W) in the SH2 domain of ITK, representing the first molecular cause of autosomal recessive lymphoproliferative dis- ease. Arginine 335 is found in the ‘BG loop’ not involved in phosphotyrosine binding and mutation to tryptophan most probably causes instability of the SH2 domain. Thus, these patients had undetectable levels of ITK protein despite normal levels of mRNA. Consistent with this, in silico modeling predicted that the mutation would destabilize the SH2 domain and no R335W mutant protein was detected following overexpression in 293T cells [35]. In 2011, Stepensky et al. [42] reported three cases from a single Arab fam- ily with a biallelic, nonsense mutation in the kinase domain. The nonsense mutation, C1764G, was pre- dicted to cause a premature stop codon in the kinase domain, seemingly creating an unstable protein. All three presented with EBV-positive B-cell proliferation, which was diagnosed as Hodgkin’s lymphoma. Follow- ing chemotherapy, one patient went into stable remis- sion and one developed severe hemophagocytic lymphohistiocytosis with multiorgan failure and died. The third patient underwent successful allogeneic bone marrow transplantation. The disease resembles ITK deficiency in mouse models with the absence of natural killer T cells (NKT cells). Even though the patients with the R335W mutation completely lacked ITK protein, mutations in the ITK SH2 domain may have additional effects when the pro- tein remains stable, by acting as a dominant negative form, or by interfering with other functional parts of the molecule. Thus, as a functional SH2 domain is nec- essary for enzymatic activity, it is likely that kinase activity is also compromised in certain mutants desta- bilizing the SH2 domain in TFKs [43,44]. So far, more than 30 missense mutations in the BTK SH2 domain have been described in patients with XLA, and the effects of these mutations have been analyzed in a large number of in vitro and in vivo studies [45]. About 20 mutations affect residues directly involved in ligand binding, presumably abolishing the interaction with signaling partners. The remaining mutations alter amino acids located outside the ligand-binding pocket and reduce protein stability. The two patients with the R335W mutation had negligible levels of NKT cells. This suggests that NKT cells protect against increased susceptibility to EBV infection, EBV-positive B-cell proliferation and Hodg- kin’s lymphoma. It has been postulated that NKT cells play a critical role in the immune response to EBV infection in humans [46,47]. Accordingly, the patient’s parents, who were heterozygous for this mutation, had low, but still detectable, numbers of NKT cells, and did not succumb to severe EBV infection. In mice, it has also been shown that NKT cells play important roles in protection against virus infections [48]. The absence of ITK has been studied extensively in mouse models. ITK regulates a number of T-cell signaling pathways, including NKT cell development and func- tions; in ITK-deficient mice, the overall NKT percent- age and numbers are decreased significantly [3,40,41,49–51]. Based on the data from the two patients and the results from animal research, human ITK mutation and ITK-deficient mice also share some other common features. Apart from the reduced num- ber of NKT cells, naive T cells are also reduced in number, both CD4 + and CD8 + . Moreover, especially within the CD8 + population, a subset with memory phenotype (CD44 + , CD122 + in mice and CD45RO in humans) is increased [35,51,52]. This is also reflected in the transcriptome of both human [35] and mouse [51,53] CD8 + cells, which express very high levels of the transcription factor eomesodermin, whose own transcription is suppressed by ITK [35,51]. Another important transcriptional regulator is promyelocytic leukemia zinc finger protein, which is essential for NKT cell development and also plays a direct role in the generation of innate T cells with a memory pheno- type [54,55]. Additional patients with other mutations were recently presented at the XIVth Meeting of the European Society for Immunodeficiencies, where Huck TEC kinases and disease A. Hussain et al. 2004 FEBS Journal 278 (2011) 2001–2010 ª 2011 The Authors Journal compilation ª 2011 FEBS et al. [56] reported two new missense mutations and one family with a deletion in the ITK gene. EBV-asso- ciated lymphoproliferative disease was observed in patients with concomitant fever, lymphadenopathy, leukopenia and reduced numbers of NKT cells. ITK – a potential target for HIV drug development It is believed that 30 million people worldwide are cur- rently infected with the virus that causes AIDS. Despite intensive scientific research over the past 27 years, HIV remains defiant and poses a serious challenge to public health [57]. Although the introduc- tion of powerful drugs has considerably improved the quality of life for patients with AIDS in industrialized countries, there is, at present, no definitive cure or vac- cine. Therefore, the development of novel antiviral drugs should be a priority. Notably, the tools of mod- ern molecular biology have enabled the design of nucleic acid analogs that could modulate gene expres- sion in mammalian cells. Small interfering RNA is a case in point [58]. To this end, we and other research groups have investigated RNA interference as a treat- ment regimen for HIV ⁄ AIDS [59,60]. By employing this approach, close to 70% inhibition of viral infec- tion was achieved in cell lines stably transduced with an expression vector encoding short hairpin RNA against the CCR5 receptor. Similarly, viral replication was entirely compromised (> 90%) when cell lines expressing short hairpin RNA against the Rev protein were challenged with HIV [60]. More recently, we have demonstrated that protea- some inhibitors reduce the steady-state levels of TFKs in hematopoietic cell lines [61]. As members of this family are known to be critical in inflammatory and infectious diseases, drugs that inhibit their activity or expression are of utmost importance. ITK has recently been shown to be crucial for HIV replication in sus- ceptible cells at multiple levels [62]. In resting human CD4 + T cells, the expression of ITK is extremely low and often undetectable in immunoblot analysis. The activation of CD4 + cells, however, dramatically induces transcription of the ITK gene and is key for the productive infection of HIV in these cells. Accord- ingly, the inhibition of ITK activity compromises HIV infection, gene expression and replication [62]. Our group has recently evaluated the effect of proteasome inhibitors on HIV infection and ⁄ or replica- tion. To determine whether the depletion of ITK could affect HIV replication, we treated activated periph- eral blood mononuclear cells with the clinically approved proteasome inhibitor bortezomib (Velcade) and challenged the cells with a strain of HIV. Surpris- ingly, HIV replication was dramatically blocked [63]. Although other reasons could not be excluded, the overall reduction of ITK might be responsible for the potent viral inhibition. Moreover, novel proteasome inhibitors that are less toxic and more specific are cur- rently in the pipeline for clinical approval [64], and several ITK-specific inhibitors have been developed [33,34]. Transforming activity of the ITK–SYK fusion protein Under physiological growth conditions, SYK seems to be autoinhibited and is believed to exist in a closed conformation [65–67]. Following cellular stimulation, SYK becomes phosphorylated by an SRC family kinase and binds to the immunoreceptor tyrosine- based activation motifs at the inner surface of the plasma membrane. Binding to immunoreceptor tyro- sine-based activation motifs fixes the molecule in an extended configuration, thereby stabilizing the nonin- hibited state. Additional phosphorylation events involving multiple tyrosines, in particular those at the carboxyl terminal tail, facilitate the interaction of SYK with the adapter proteins BLNK (also known as SLP- 65) and SLP-76, making it fully active. SYK has been linked to the development and main- tenance of hematological malignancies [67]. Moreover, as a result of chromosomal translocation, a chimera, consisting of the dimerizing TEL protein and SYK, was formed and has been shown to cause a rare form of myelodysplastic syndrome [68]. Recently, ITK was the first and only known Tec family member reported to undergo a chromosomal translocation event leading to a chimeric kinase with transforming capacity, the hallmark of which is unspecified peripheral T-cell lymphoma [69]. Conse- quently, the PH–TH domain doublet of ITK fuses directly with the linker B kinase region of SYK. The PH domain of TFKs usually binds to phosphatidylino- sitol-3,4,5-trisphosphate, thereby bringing them in close proximity to other membrane-tethered signaling proteins. In SYK, the linker B region contains key tyrosines that are subject to auto- and ⁄ or transphosph- orylation, and that mediate interaction with Vav, c-Cbl and the p85a subunit of phosphatidylinositol 3-kinase, whereas the kinase domain harbors two unique tyrosines (the paired activation loop tyrosines) critical for activation and signaling [65–67]. The fusion event creates a novel kinase with a unique composition that probably favors an open conformation structure, with the potential for constitutive activation. Thus, A. Hussain et al. TEC kinases and disease FEBS Journal 278 (2011) 2001–2010 ª 2011 The Authors Journal compilation ª 2011 FEBS 2005 ITK–SYK, but not ITK or SYK themselves, is capable of transforming NIH-3T3 cells [70]. In addition, we and others have demonstrated that the activation and plasma membrane localization of the fusion construct are dependent on phosphatidylinositol 3-kinase signal- ing, and that ITK–SYK phosphorylates the adapter proteins SLP-76 and BLNK in the absence of external stimuli [70–72]. More recently, a transgenic mouse expressing the ITK–SYK fusion under the control of a T-cell-specific promoter [72], as well as another mouse model in which bone marrow cells were transduced with a vec- tor expressing ITK–SYK [73], have been described. Expression of the chimera resulted in the formation of highly malignant peripheral T-cell lymphomas in mice, with a phenotype resembling that described in human patients. In T cells from transgenic mice, the ITK– SYK fusion was found to translocate to lipid rafts and was able to constitutively phosphorylate T-cell recep- tor-associated signaling proteins. It is noteworthy that, when the same fusion construct was specifically expressed in the B-cell lineage of these animals, it did not induce the formation of B-cell lymphomas. Thus, transgenic mice with a CD19 promoter-mediated expression of ITK–SYK failed to develop B-cell lym- phoma but, instead, yielded T-cell tumors, albeit with considerable delay, probably caused by promoter leaki- ness [72]. Unexpectedly, in the transduced model, the R29C mutant (corresponding to BTK R28C), which lacks the membrane-targeting ability, showed enhanced tumorigenicity. These findings underline the surpris- ingly stark differences between B and T lymphocytes with regard to their response to different TFK fusions, and also raises the important question of the outcome of the corresponding translocation involving BTK in B lymphocytes generating BTK–SYK. Will such a fusion behave differently from ITK–SYK in terms of transformation capacity, membrane localization and phosphorylation of key residues? Comparison between the activation of ITK–SYK and BTK–SYK To determine its activation capacity, we constructed the corresponding fusion kinase BTK–SYK, harboring the PH–TH domain doublet (amino acids 1–196) of BTK fused with the linker B kinase region of SYK (306–635 amino acids) (Fig. 2). We used two different cell types to study the phosphorylation status of key residues and the capacity to phosphorylate exogenous substrate molecules. BTK–SYK, like ITK–SYK, proved to be constitu- tively active in transiently transfected COS7 cells (Fig. 2B). In addition to the full-length fusion protein, ITK–SYK produces a very stable and shorter protein in COS7 and 293T cells. This shorter isoform, which can also be phosphorylated, is generated as a result of alternative translation initiation. BTK–SYK also pro- duces a similar isoform which, in contrast with ITK– SYK, is highly unstable as a result of degradation by the ubiquitin–proteasome pathway (A. Hussain et al., unpublished results). In COS7 cells, the fusion protein was highly phosphorylated in the linker region and in the activation loop tyrosines in the absence of any external stimulation. Moreover, BTK–SYK also showed similar phosphorylation when expressed at lev- els comparable with those of endogenous SYK in 293T cells. The kinase-deficient versions of the fusion proteins were not readily phosphorylated in either cell type. In particular, the phosphorylation, but also the total protein level, of BTK–SYK was less than that of ITK– SYK in 293T relative to COS7 cells. 293T cells express endogenous SYK, but we do not know whether this kinase influences the behavior of the fusion proteins. It is also possible that the differential expression of SRC family members in these two cell types may influence the phosphorylation levels of BTK–SYK. ITK–SYK was highly phosphorylated in both COS7 and 293T cells and did not vary like BTK–SYK; therefore, the differences in the PH–TH domains remain the decisive factor for this variation. The B-cell adapter protein BLNK (SLP-65) and its T-cell counterpart SLP-76 are key signaling compo- nents downstream of immunoreceptors. ITK–SYK has been reported to potently phosphorylate SLP-76 in the steady state [71,72]. Coexpression of BLNK or SLP-76 with BTK–SYK or ITK–SYK resulted in robust phos- phorylation of the two adapter molecules in 293T cells. The phosphorylation levels of BLNK and SLP-76 in cells transfected with BTK–SYK were, however, lower relative to ITK–SYK, consistent with the reduced phosphorylation level of BTK–SYK itself in these cells. In COS7 cells, where BTK–SYK and ITK–SYK are equally phosphorylated, phosphorylation of SLP- 76 and BLNK was essentially the same on cotransfec- tion with either of the two fusion proteins (Fig. 2B). In both cell types, kinase-inactive forms of the fusion proteins failed to phosphorylate BLNK and SLP-76. Thus, we found that BTK–SYK and ITK–SYK were different in terms of their activation and substrate phosphorylation levels in different cell lines. This study shows that seemingly subtle differences in the PH–TH domains of the two fusion proteins play key roles in the activation process and are responsible for varia- tions among different cell types. TEC kinases and disease A. Hussain et al. 2006 FEBS Journal 278 (2011) 2001–2010 ª 2011 The Authors Journal compilation ª 2011 FEBS In conclusion, TFKs form a family of cytoplasmic enzymes that are important for several aspects of leu- kocyte biology. Both loss- and gain-of-function muta- tions in humans have been instrumental in our understanding of their behavior. Acknowledgements This work was supported by the Swedish Science Council, the Stockholm County Council (research grant ALF-projektmedel medicin), the Cancer Founda- tion, the European Union FP7 grant EURO-PADnet, and the Torsten and Ragnar So ¨ derberg Foundation. Rani Faryal was a recipient of a Postdoctoral Fellow- ship from the Higher Education Commission (HEC), Pakistan. We are indebted to Dr Jouni Va ¨ liaho, Uni- versity of Tampere, Finland, for modifications to Fig. 1. Dara K. Mohammad was a recipient of a PhD Fellowship from the Ministry of Higher Education and Scientific Research ⁄ KRG-Erbil, Iraq. References 1 Ortutay C, Nore BF, Vihinen M & Smith CI (2008) Phylogeny of Tec family kinases: identification of a premetazoan origin of Btk, Bmx, Itk, Tec, Txk, and the Btk regulator SH3BP5. Adv Genet 64, 51–80. 2 Hamada N, Backesjo CM, Smith CI & Yamamoto D (2005) Functional replacement of Drosophila Btk29A with human Btk in male genital development and survival. FEBS Lett 579, 4131–4137. 3 Andreotti AH, Schwartzberg PL, Joseph RE & Berg LJ (2010) T-cell signaling regulated by the Tec family kinase, Itk. Cold Spring Harb Perspect Biol doi:10.1101/cshperspect.a002287. 4 Koprulu AD & Ellmeier W (2009) The role of Tec family kinases in mononuclear phagocytes. Crit Rev Immunol 29, 317–333. 5 Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, Christensson B, Berglof A, Vihinen M, Nore BF et al. (2009) Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 228, 58–73. 6 Readinger JA, Mueller KL, Venegas AM, Horai R & Schwartzberg PL (2009) Tec kinases regulate T-lympho- cyte development and function: new insights into the roles of Itk and Rlk ⁄ Txk. Immunol Rev 228, 93–114. 7 Smith CI, Islam TC, Mattsson PT, Mohamed AJ, Nore BF & Vihinen M (2001) The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays 23, 436–446. 8 Freudenberg J, Lee AT, Siminovitch KA, Amos CI, Ballard D, Li W & Gregersen PK (2010) Locus cate- gory based analysis of a large genome-wide association study of rheumatoid arthritis. Hum Mol Genet 19, 3863–3872. 9 Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S et al. (1993) Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72, 279–290. 10 Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, Kinnon C, Levinsky R, Bobrow M et al. (1993) The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361, 226–233. 11 Thomas JD, Sideras P, Smith CIE, Vorechovsky I, Chapman V & Paul WE (1993) Colocalization of X-linked agammaglobulinemia and X-linked immuno- deficiency genes. Science 261, 355–358. 12 Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, Mohr RN, Bazan JF, Howard M, Copeland NG et al. (1993) Mutation of unique region of Bruton’s tyrosine kinase in immuno- deficient XID mice. Science 261, 358–361. 13 Vihinen M, Belohradsky BH, Haire RN, Holinski-Feder E, Kwan SP, Lappalainen I, Lehvaslaiho H, Lester T, Meindl A, Ochs HD et al. (1997) BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic Acids Res 25, 166–171. 14 Ellmeier W, Jung S, Sunshine MJ, Hatam F, Xu Y, Baltimore D, Mano H & Littman DR (2000) Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J Exp Med 192, 1611–1624. 15 Salim K, Bottomley MJ, Querfurth E, Zvelebil MJ, Gout I, Scaife R, Margolis RL, Gigg R, Smith CI, Driscoll PC et al. (1996) Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton’s tyrosine kinase. EMBO J 15 , 6241–6250. 16 Franke TF, Kaplan DR, Cantley LC & Toker A (1997) Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275 , 665–668. 17 Sable CL, Filippa N, Filloux C, Hemmings BA & Van Obberghen E (1998) Involvement of the pleckstrin homology domain in the insulin-stimulated activation of protein kinase B. J Biol Chem 273, 29600–29606. 18 Vihinen M, Nore BF, Mattsson PT, Backesjo CM, Nars M, Koutaniemi S, Watanabe C, Lester T, Jones A, Ochs HD et al. (1997) Missense mutations affecting a conserved cysteine pair in the TH domain of Btk. FEBS Lett 413, 205–210. 19 Valiaho J, Smith CI & Vihinen M (2006) BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat 27, 1209–1217. 20 Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S, Coustan-Smith E, Howard V & A. Hussain et al. TEC kinases and disease FEBS Journal 278 (2011) 2001–2010 ª 2011 The Authors Journal compilation ª 2011 FEBS 2007 Campana D (2009) Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol 27, 199–227. 21 Lindvall JM, Blomberg KE, Valiaho J, Vargas L, Hei- nonen JE, Berglof A, Mohamed AJ, Nore BF, Vihinen M & Smith CI (2005) Bruton’s tyrosine kinase: cell biol- ogy, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 203, 200–215. 22 Holinski-Feder E, Weiss M, Brandau O, Jedele KB, Nore B, Backesjo CM, Vihinen M, Hubbard SR, Beloh- radsky BH, Smith CI et al. (1998) Mutation screening of the BTK gene in 56 families with X-linked agamma- globulinemia (XLA): 47 unique mutations without cor- relation to clinical course. Pediatrics 101, 276–284. 23 Perez de Diego R, Bravo J, Allende LM, Lopez-Grana- dos E, Rivera J, Ferreira A, Fontan G & Garcia Rodri- guez MC (2008) Identification of novel non-pathogenic mutation in SH3 domain of Btk in an XLA patient. Mol Immunol 45, 301–303. 24 Hansson H, Mattsson PT, Allard P, Haapaniemi P, Vihinen M, Smith CI & Hard T (1998) Solution struc- ture of the SH3 domain from Bruton’s tyrosine kinase. Biochemistry 37, 2912–2924. 25 Wood PM, Mayne A, Joyce H, Smith CI, Granoff DM & Kumararatne DS (2001) A mutation in Bruton’s tyrosine kinase as a cause of selective anti-polysaccha- ride antibody deficiency. J Pediatr 139, 148–151. 26 Ochs HD & Smith CI (1996) X-linked agammaglobulin- emia. A clinical and molecular analysis. Medicine (Baltimore) 75, 287–299. 27 Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, Cazzola G, Consolini R, De Mattia D, Dell’Erba G et al. (2002) Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 104, 221–230. 28 Ellmeier W, Abramova A & Schebesta A (2011) Tec family kinases: regulation of FcepsilonRI-mediated mast cell activation. FEBS J 278, 1990–2000. 29 Quartier P, Debre M, De Blic J, de Sauverzac R, Say- egh N, Jabado N, Haddad E, Blanche S, Casanova JL, Smith CI et al. (1999) Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 134, 589–596. 30 Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, Hammarstrom L, Jacobsen MB, Jonsson E, Moller G et al. (1995) Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 345, 365–369. 31 Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M & Ochs HD (2009) Subcuta- neous immunoglobulin: opportunities and outlook. Clin Exp Immunol 158(Suppl 1), 51–59. 32 Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA et al. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107, 13075–13080. 33 Lo HY (2010) Itk inhibitors: a patent review. Expert Opin Ther Pat 20, 459–469. 34 Sahu N & August A (2009) ITK inhibitors in inflamma- tion and immune-mediated disorders. Curr Top Med Chem 9, 690–703. 35 Huck K, Feyen O, Niehues T, Ruschendorf F, Hubner N, Laws HJ, Telieps T, Knapp S, Wacker HH, Meindl A et al. (2009) Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 119, 1350–1358. 36 Siliciano JD, Morrow TA & Desiderio SV (1992) itk, a T-cell-specific tyrosine kinase gene inducible by interleu- kin 2. Proc Natl Acad Sci USA 89, 11194–11198. 37 Gibson S, Leung B, Squire JA, Hill M, Arima N, Goss P, Hogg D & Mills GB (1993) Identification, cloning, and characterization of a novel human T-cell-specific tyrosine kinase located at the hematopoietin complex on chromosome 5q. Blood 82, 1561–1572. 38 Mueller C & August A (2003) Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK. J Immunol 170, 5056–5063. 39 Matsumoto Y, Oshida T, Obayashi I, Imai Y, Matsui K, Yoshida NL, Nagata N, Ogawa K, Obayashi M, Kashiwabara T et al. (2002) Identification of highly expressed genes in peripheral blood T cells from patients with atopic dermatitis. Int Arch Allergy Immunol 129, 327–340. 40 Gomez-Rodriguez J, Kraus ZJ & Schwartzberg PL (2011) Tec family kinases Itk and Rlk ⁄ Txk in T lym- phocytes: cross-regulation of cytokine production and T cell fates. FEBS J 278, 1980–1989. 41 Qi Q, Kannan AK & August A (2011) Tec family kinases: Itk signaling and the development of NKT alphabeta and gammadelta T cells. FEBS J 278, 1970–1979. 42 Stepensky P, Weintraub M, Yanir A, Revel-Vilk S, Krux F, Huck K, Linka RM, Shaag A, Elpeleg O, Borkhardt A et al. (2011) IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica 96, 472–476. 43 Joseph RE, Min L & Andreotti AH (2007) The linker between SH2 and kinase domains positively regulates catalysis of the Tec family kinases. Biochemistry 46, 5455–5462. TEC kinases and disease A. Hussain et al. 2008 FEBS Journal 278 (2011) 2001–2010 ª 2011 The Authors Journal compilation ª 2011 FEBS 44 Guo S, Wahl MI & Witte ON (2006) Mutational analy- sis of the SH2-kinase linker region of Bruton’s tyrosine kinase defines alternative modes of regulation for cyto- plasmic tyrosine kinase families. Int Immunol 18, 79–87. 45 Lappalainen I, Thusberg J, Shen B & Vihinen M (2008) Genome wide analysis of pathogenic SH2 domain mutations. Proteins 72, 779–792. 46 Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Lau- cat F, Revy P et al. (2006) XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444, 110–114. 47 Pasquier B, Yin L, Fondaneche MC, Relouzat F, Bloch-Queyrat C, Lambert N, Fischer A, de Saint- Basile G & Latour S (2005) Defective NKT cell devel- opment in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 201, 695–701. 48 Kakimi K, Guidotti LG, Koezuka Y & Chisari FV (2000) Natural killer T cell activation inhibits hepati- tis B virus replication in vivo. J Exp Med 192 , 921–930. 49 Felices M & Berg LJ (2008) The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival. J Immunol 180, 3007–3018. 50 Au-Yeung BB & Fowell DJ (2007) A key role for Itk in both IFN gamma and IL-4 production by NKT cells. J Immunol 179, 111–119. 51 Atherly LO, Lucas JA, Felices M, Yin CC, Reiner SL & Berg LJ (2006) The Tec family tyrosine kinases Itk and Rlk regulate the development of conventional CD8+ T cells. Immunity 25, 79–91. 52 Broussard C, Fleischacker C, Horai R, Chetana M, Venegas AM, Sharp LL, Hedrick SM, Fowlkes BJ & Schwartzberg PL (2006) Altered development of CD8+ T cell lineages in mice deficient for the Tec kinases Itk and Rlk. Immunity 25, 93–104. 53 Blomberg KE, Boucheron N, Lindvall JM, Yu L, Raberger J, Berglof A, Ellmeier W & Smith CE (2009) Transcriptional signatures of Itk-deficient CD3+, CD4+ and CD8+ T-cells. BMC Genomics 10, 233. 54 Raberger J, Schebesta A, Sakaguchi S, Boucheron N, Blomberg KE, Berglof A, Kolbe T, Smith CI, Rulicke T & Ellmeier W (2008) The transcriptional regulator PLZF induces the development of CD44 high memory phenotype T cells. Proc Natl Acad Sci USA 105, 17919–17924. 55 Weinreich MA, Odumade OA, Jameson SC & Hogquist KA (2010) T cells expressing the transcription factor PLZF regulate the development of memory-like CD8+ T cells. Nat Immunol 11, 709–716. 56 Huck K, Feyen O, Ruschendorf F, Knapp S, Niehues T, Synaeve C, Latour S, Vettenranta K, Risse SL, Krux F et al. (2010) A novel immunodeficiency due to muta- tions in ITK causes an EBV-associated lymphoprolifer- ative disease in children. In XIVth Meeting of the European Society for Immunodeficiencies (Casanova JL & Kutukculer N, eds), p 56. Topkon Congress Services, Kadikoy-Istanbul, Turkey. 57 Piot P, Bartos M, Ghys PD, Walker N & Schwartland- er B (2001) The global impact of HIV ⁄ AIDS. Nature 410, 968–973. 58 Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K & Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mamma- lian cells. Nature 411, 494–498. 59 Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shan- kar P & Sharp PA (2002) siRNA-directed inhibition of HIV-1 infection. Nat Med 8, 681–686. 60 Arteaga HJ, Hinkula J, van Dijk-Hard I, Dilber MS, Wahren B, Christensson B, Mohamed AJ & Smith CI (2003) Choosing CCR5 or Rev siRNA in HIV-1. Nat Biotechnol 21, 230–231. 61 Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE, Bjorkstrand B, Arteaga HJ, Nore BF & Smith CI (2008) Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 111, 4617–4626. 62 Readinger JA, Schiralli GM, Jiang JK, Thomas CJ, August A, Henderson AJ & Schwartzberg PL (2008) Selective targeting of ITK blocks multiple steps of HIV replication. Proc Natl Acad Sci USA 105, 6684–6689. 63 Yu L, Mohanram V, Simonson OE, Smith CI, Spetz AL & Mohamed AJ (2009) Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets. Biochem Biophys Res Commun 385, 100–105. 64 Yang H, Zonder JA & Dou QP (2009) Clinical develop- ment of novel proteasome inhibitors for cancer treat- ment. Expert Opin Investig Drugs 18, 957–971. 65 Kulathu Y, Grothe G & Reth M (2009) Autoinhibition and adapter function of Syk. Immunol Rev 232, 286– 299. 66 Geijtenbeek TB & Gringhuis SI (2009) Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 9, 465–479. 67 Mocsai A, Ruland J & Tybulewicz VL (2010) The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 10, 387–402. 68 Kuno Y, Abe A, Emi N, Iida M, Yokozawa T, Towa- tari M, Tanimoto M & Saito H (2001) Constitutive kinase activation of the TEL–Syk fusion gene in myelo- dysplastic syndrome with t(9;12)(q22;p12). Blood 97, 1050–1055. 69 Streubel B, Vinatzer U, Willheim M, Raderer M & Chott A (2006) Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leuke- mia 20, 313–318. 70 Rigby S, Huang Y, Streubel B, Chott A, Du MQ, Turner SD & Bacon CM (2009) The lymphoma-associ- ated fusion tyrosine kinase ITK–SYK requires pleck- A. Hussain et al. TEC kinases and disease FEBS Journal 278 (2011) 2001–2010 ª 2011 The Authors Journal compilation ª 2011 FEBS 2009 strin homology domain-mediated membrane localiza- tion for activation and cellular transformation. J Biol Chem 284, 26871–26881. 71 Hussain A, Faryal R, Nore BF, Mohamed AJ & Smith CI (2009) Phosphatidylinositol-3-kinase-dependent phosphorylation of SLP-76 by the lymphoma-associated ITK–SYK fusion-protein. Biochem Biophys Res Commun 390, 892–896. 72 Pechloff K, Holch J, Ferch U, Schweneker M, Brunner K, Kremer M, Sparwasser T, Quintanilla-Martinez L, Zimber-Strobl U, Streubel B et al. (2010) The fusion kinase ITK–SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med 207, 1031– 1044. 73 Dierks C, Adrian F, Fisch P, Ma H, Maurer H, Her- chenbach D, Forster CU, Sprissler C, Liu G, Rottmann S et al. (2010) The ITK–SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res 70, 6193–6204. TEC kinases and disease A. Hussain et al. 2010 FEBS Journal 278 (2011) 2001–2010 ª 2011 The Authors Journal compilation ª 2011 FEBS . MINIREVIEW TEC family kinases in health and disease – loss -of- function of BTK and ITK and the gain -of- function fusions ITK SYK and BTK SYK Alamdar. review these disease processes and also describe the role of the N-terminal pleckstrin homology Tec homology (PH–TH) domain doublet of BTK and ITK in the